



CI Insight Report

- SSc -

[Sample Table of Contents]

January 2024

Social Survey Research Information Co., Ltd.

§ Report TOPICS

Diseases under investigation	SSc (systemic sclerosis)	
Survey Points/ Topics	Patient trends	<ul style="list-style-type: none"> ➤ Analysis and verification of SSc patient trends ➤ Analysis and verification of SSc patient consultation status/background of consultation ➤ Analysis and verification of the appearance of each lesion and symptom, <u>focusing on skin hardening and interstitial lung disease</u> <p>⇒ In-depth analysis of the actual status of SSc patients by disease type (dcSSc/lcSSc)!</p>
	Drug therapy	<ul style="list-style-type: none"> ➤ Analysis and verification of drug prescription status, <u>focusing on skin hardening and interstitial lung disease</u> ⇒ What are the trends in prescription drugs for skin hardening and interstitial lung disease? ➤ Verification of current treatment results ➤ Forecast of future prescribing trends by drug <p>⇒ In-depth verification of the actual status of drug therapy and unmet needs for existing treatment!</p> <p>⇒ In-depth forecast of future trends in therapeutic drug prescriptions!</p>
	New drugs	<ul style="list-style-type: none"> ➤ Verification and forecast of the potential and prescribing trends of a high-profile drug, brodalumab ➤ Verification of the potential of drugs (in the late-stage of development) <p>⇒ In-depth verification of the potential of new drugs!</p>

§ Report TOPICs

Diseases under investigation	SSc (systemic sclerosis)	
Survey Points/ Topics	Clinical development direction	<ul style="list-style-type: none">➤ Analysis and verification of past development failure factors➤ Verification of key points for successful development<ul style="list-style-type: none">⇒ In-depth forecast of the direction of future clinical development! (What is the trigger for obtaining approval? How is the primary endpoint set up?)

■ Major Survey Subjects

***Underlined and bolded items are the focus of the survey.**

Lesions/Symptoms		<ul style="list-style-type: none"> •<u>Skin hardening, interstitial lung disease</u>, Raynaud's symptoms, skin ulcers •Raynaud's symptoms, skin ulcers •Pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease •Upper gastrointestinal symptoms, lower gastrointestinal symptoms 	
Remedy	Existing drugs	Steroid	Oral/injectable steroids
		Immunosuppressant	Endoxan, cyclosporine, tacrolimus, <u>Cellcept</u>
		Biological drug	<u>Rituximab, Actemra</u>
		Tyrosine kinase inhibitor/antifibrotic agent	Ofev
		Other	Endothelin receptor antagonists, PDE5 inhibitors, prostacyclin preparations, immunoglobulin preparations
	New drugs (developed drugs) <Expansion of indications>	Anti-IL-17 receptor A antibody	<u>Brodalumab (Lumicef)</u>
		Anti-CD19 monoclonal antibody	Inebilizumab (Uplizna)
		Anti-type I interferon receptor antibody	Anifrolumab (Saphnelo)
		Anti-human IL-23p19 monoclonal antibody	Guselkumab (Tremfya)
		Fully human anti-BLyS monoclonal antibody	Belimumab (Benlysta)
		Anti-human IL-31 receptor A monoclonal antibody	Nemolizumab (Mitchga)

§ Summary by Report Part

Survey type	Part I Data analysis	Part II Quantitative survey	Part III KOL hearing
Survey method	Data analysis (based on open source)	Web survey via the Internet	Depth interview
Physicians surveyed/ Number of physicians surveyed	-	SSc clinicians Total 200	SSc TOP KOL 3 [board members of related academic societies]
Departments surveyed <Facility Type>	-	Rheumatology/collagen diseases, dermatology, internal medicine <HP/GP>	Dermatology/collagen diseases <HP>
Survey contents	<Existing drugs> List of therapeutic agents, clinical trials, related papers <Developed drugs (domestic/overseas)> Profile, mechanism of action/characteristics, clinical trials, related literatures <Others> Trends in notable companies, information on related academic societies <Attachment> Abstracts (related papers)	<Medical treatment/patient trends> <ul style="list-style-type: none"> ● Patient trends by disease type (dcSSc/lcSSc) ● Consultation status/background of consultation ● Patient status by duration of disease onset (dcSSc) <Appearance by lesion/symptom> <ul style="list-style-type: none"> ● Appearance by lesion/symptom ● Lesions and symptoms of therapeutic importance (other than skin hardening) <Drug therapy status for skin hardening/interstitial lung disease> <ul style="list-style-type: none"> ● Prescription status by drug ● Treatment satisfaction by drug ● Percentage of patients with poor response to treatment ● Future prescribing trends by drug 	<Medical treatment/patient trends> <ul style="list-style-type: none"> ● Status of medical treatment/background of consultation ● Medical treatment/patient trends in Japan* <Appearance by lesion/symptom> <ul style="list-style-type: none"> ● Appearance of major lesions and symptoms ● Lesions and symptoms of therapeutic importance <Drug therapy implementation status> <ul style="list-style-type: none"> ● Drug therapy implementation status/therapeutic drug prescribing status for skin hardening and interstitial lung disease* ● Prescription status of therapeutic drugs in Japan* ● Forecast of therapeutic drug prescribing trends* ● Unmet needs for existing treatment*

§ Summary by Report Part

Survey type	Part I Data analysis	Part II Quantitative survey	Part III KOL hearing
Survey contents		<p><Forecast of prescribing trends of a new drug, brodalumab></p> <ul style="list-style-type: none"> ● Awareness by drug ● Prescribing intention/expectation ● Prescription targets <p><Unmet needs for existing treatment></p> <p style="text-align: right;">and so forth</p>	<p><New drug evaluation and forecast of prescribing trends></p> <ul style="list-style-type: none"> ● Evaluation of brodalumab/forecast of prescribing trends* ● Potential analysis by drug (other than brodalumab) <p><Direction of clinical development></p> <ul style="list-style-type: none"> ● Future direction of clinical development* <p style="text-align: right;">and so forth</p> <p>*The verification/forecast of <u>actual situations/future trends in whole Japan</u> is included.</p>
Survey period	November - December 2023		
Style/Pages	Part I - PPT (or EXCEL), Part II & III - PPT / A4 total 300 pages (main report only, not including attachments)		
Report price	<p>Full set of report <3 parts> 1,900,000 yen (tax not included) *Parts can be sold separately</p> <p>*Option Row data 500,000 yen (tax not included)</p> <p>Row data + target matching 600,000 yen (tax not included)</p>		

<Part I Data Analysis Table of Contents>

Survey summary	3	IV. Information on academic societies	38
I. Existing products	4	IV-1. The Japan College of Rheumatology	39
I-1. Profile	5	IV-2. The Japanese Society for Clinical Rheumatology and Related Research	41
I-2. Mechanism of action/characteristics	9	IV-3. Pediatric Rheumatology Association of Japan	43
I-3. Drug price	13	IV-4. The Japanese Society of Clinical Immunology	44
I-4. Clinical trials (UMIN)	16	IV-5. Japanese Dermatological Association	45
I-5. Clinical trials(jRCT)	18	IV-6. The Japanese Society of Inflammation and Regeneration	46
I-6. Clinical trials (UMIN&jRCT)	19	V. Related literatures	47
II. Developed products	20	V-1-1. Existing products (by product)	48
II -1. Profile	21	V-1-2. Existing products (multiple)	54
II -2. Mechanism of action/characteristics	24	V-2. Developed products	55
II -3. Clinical trials (jRCT)	28	V-3. Existing products + developed products	57
III. Related company trends	30		

<Part II Quantitative Survey **Summary** Table of Contents>

Survey summary	3
Respondent profile	4
§.Executive summary	5
§.Summary	12
1) Status of medical treatment	13
2) Overall implementation status of drug therapy (SSc)	19
3) Trends in the implementation of drug therapy for skin hardening	25
4) Trends in the implementation of drug therapy for interstitial lung disease	48
5) Awareness and prescribing trends of brodalumab	71
6) Intention to prescribe developed drugs	76
7) Unmet needs for existing treatment	78

<Part II Quantitative Survey Results Table of Contents>

Survey summary	3	3-5. Treatment satisfaction by drug	46
Respondent profile	4	3-6. Future prescribing trends by drug	50
§ Survey results	5	3-7. Percentage of patients with poor poor/inadequate treatment response	54
1) Status of medical treatment	6	4) Trends in the implementation of drug therapy for interstitial lung disease	55
1-1. Number of patients treated and new patients (in the last 6 months)	7	4-1. Patient status by pulmonary function status (diffuse cutaneous type)	56
1-2. Percentage of patients by disease type	8	4-2. Drug therapy implementation status	57
1-3. Consultation status (background of consultation)	9	4-3. Prescription status of therapeutic drugs	60
1-4. Patient status by duration of disease onset (diffuse cutaneous type)	10	4-4. Prescription status by drug (in the last 6 months)	62
1-5. Appearance by symptom	11	4-5. Treatment satisfaction by drug	78
2) Overall implementation status of drug therapy (SSc)	19	4-6. Future prescribing trends by drug	83
2-1. Factors to consider when selecting a drug	20	4-7. Percentage of patients with poor/inadequate treatment response	88
2-2. Lesions and symptoms to focus on (other than skin hardening)	21	5) Awareness and prescribing trends of brodalumab	89
2-3. Therapeutic drug prescription status	24	5-1. Awareness status	90
3) Trends in the implementation of drug therapy for skin hardening	26	5-2. Post-approval prescribing intention	91
3-1. Patient status by skin hardening status (diffuse cutaneous type)	27	5-3. Prescription targets	92
3-2. Drug therapy implementation status	28	6) Intention to prescribe developed drugs	97
3-3. Prescription status of therapeutic drugs	31	7) Unmet needs for existing treatment	101
3-4. Prescription status by drug (in the last 6 months)	33		

<Part III KOL Hearings Table of Contents>

Survey summary	3
Summary	6
1. Patient trends	18
2. Lesion/symptom appearance	21
3. Drug therapy implementation status	25
4. Unmet needs for existing treatment	32
5. Evaluation and impression of new drugs (developed drugs)	34
6. Forecast of therapeutic drug prescribing trends	38
7. Direction of clinical development	41